Supplementary Material for: Different Responses to a High-Fat Diet in IL-6 Conditional Knockout Mice Driven by Constitutive GFAP-Cre and Synapsin 1-Cre Expression by Fernández-Gayol O. (6822389)

datasheet2_The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice.zip by Qin-Juan Sun (10067788)

datasheet1_The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice.pdf by Qin-Juan Sun (10067788)

DataSheet_1_Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer.docx by Damian Kołat (10192637)

DataSheet_1_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.xlsx by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Image_1_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.jpeg by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Image_2_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.jpeg by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Image_5_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.jpeg by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Image_3_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.jpeg by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Image_4_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.jpeg by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

DataSheet_2_Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis.docx by Takeshi Iwasaki (3279906)

“…The expression of type II IFN signaling-related genes did not significantly differ before treatment; however, it increased in non-responders and decreased in responders, with a significant difference being observed after three months of treatment (P = 1.2×10^-3). …”

Table3_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.pdf by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Table2_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.pdf by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Table2_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.pdf by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Image1_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.tiff by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Table4_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.pdf by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Image_2_Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66.PNG by Lanxin Luo (5868185)

“…</p><p>Results: Rb⁺ influx assay showed that 10 μM BMT markedly decreased the total Rb⁺ influx and no additional inhibition detected at >10 μM BMT. …”

Data Sheet 1_Pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer in a real-world setting: a population-based study.docx by Lina Cadili (21448478)

“…Among patients receiving LCRT, the 5-year OS rate was higher (69.8%) when surgery followed LCRT by 6–10 weeks compared to those undergoing surgery <6 weeks or 10+ weeks post-LCRT (p = .003).…”

Table3_Gastrointestinal cell injury and perceived symptoms after running the Boston Marathon.pdf by Melani R. Kelly (10287310)

“…A total of 40 runners (males: n = 19, age = 44.9 ± 10.8 years; females: n = 21, age = 44.8 ± 10.6 years) completed this study. …”

Table_1_Incidence, Progression, and Patterns of Multimorbidity in Community-Dwelling Middle-Aged Men and Women.docx by Xianwen Shang (311546)

“…This study aimed to analyze major multimorbidity patterns and the association of the onset of a primary condition or combinations of a primary and a secondary condition with the progression to subsequent conditions.</p><p>Methods: We included 53,867 participants aged 45–64 years from the 45 and Up Study who were free of 10 predefined chronic conditions at baseline (2006–2009). …”